Is adalimumab protective in ischemia‐reperfusion injury in lung?

Abstract

Objective(s): Increasing cytokines and reactive oxygen species (ROS) during ischemia reperfusion (I?R) leads to the lung damage. Adalimumab (Ada) is a potent tumor necrosis factor?alpha (TNF??) inhibitor agent. We aimed to evaluate whether Ada would prevent the lung tissue from damage development over the I?R process. Materials and Methods: Twenty seven Wistar albino male rats were divided into three groups (each group had 9 rats). To the control group, only laparotomy procedure was carried out. For I?R group, first infrarenal abdominal aorta was cross?clamped during 2 hr, and then reperfusion was performed for 2 hr. To I?R+Ada group, first a single dose of 50 mg/kg Ada was given intraperitoneally and 5 days later, same I?R procedure was carried out. Results: Levels of TNF??, malondialdehyde (MDA), myeloperoxidase (MPO), endothelin?1 (ET?1) and caspase?3 enzyme activity of I?R group were higher than that of both I?R+ Ada [TNF?? (P=0.021), MDA (P=0.029), MPO (P=0.012), ET?1 (P=0.036, caspase?3 (P=0.007), respectively] and control group [TNF?? (P=0.008), MDA (P<0.001), MPO (P=0.001), ET?1 (P<0.001), caspase?3 (P<0.001), respectively]. In IR group, severe damage was detected by hematoxylin?eosin staining. This damage was found less severe in Ada treatment group. Conclusion: The release of cytokines and ET?1 in a large proportion after I?R injury, and generating of ROS in excessive quantity could cause severe damage in the lung tissue. Ada could be considered as a protective agent for lung tissue during I?R process. © 2015, Mashhad University of Medical Sciences. All rights reserved.